Manufacturing Intelligence for CDMO Teams
Start each day with curated headlines on CDMO capacity, regulatory signals, and supply-chain moves — then read weekly deep dives that explain what changed structurally and how sponsors should adjust shortlists.
Feed: /api/seo/feed · Markdown mirrors: /posts/<slug>.md
- Daily newsCDMO Daily News — October 22, 2026
- ESTEVE CDMO Invests $80M to Expand Manufacturing in China
- Daily newsCDMO Daily News — October 21, 2026
- Axplora’s Strategic Partnerships Cut ADC Payload Timelines and Expand HPAPI Capacity
- Daily newsCDMO Daily News — October 16, 2026
- Genezen to Manufacture AAV Gene Therapy for SSADH Deficiency
- Lonza Expands Accelerated DNA-to-IND Platform to Bispecific Antibodies and Fc-Fusion Proteins
- Piramal Embeds Patient Centricity as Operational Decision Rule Across 15 Global Sites
- Deep diveBiologics CDMO capacity is expanding, but not fast enough for the reshuffled supply chain in 2026
Biologics CDMO capacity is growing faster than ever, but geopolitical shifts and specialty format demand are creating acute shortages in specific regions and modalities where sponsors need slots now. Companies forced to abandon Chinese partners face a compressed timeline that favors established Western players with immediate availability,
- Daily newsCDMO Daily News — October 7, 2026
- Curia Invests $28M to Expand Sterile API Manufacturing in Spain
- Catalent Launches 10-Month Gene-to-Drug Substance Program for Complex Biologics
- Flamma Acquires Lundbeck's Padova API Site, Adding 220 m³ Italian Capacity
- Genezen to Manufacture AAV8 Gene Therapy for InterAct Therapeutics Breast Cancer Program
- Daily newsCDMO Daily News — October 6, 2026
- Lonza and Asimov Partner on Lentiviral Vector GMP Manufacturing
- Curia Invests $28M in Sterile API Expansion at Valladolid Site
- MedPharm Lands Fifth Commercial Manufacturing Deal in 20 Months
- Daily newsCDMO Daily News — October 4, 2026
- Lonza and Asimov Partner on Scalable Lentiviral Vector Manufacturing for Gene Therapy
- Daily newsCDMO Daily News — October 3, 2026
- Biomay and Synthego Partner on Integrated cGMP CRISPR Manufacturing
- Lonza and Asimov Partner on Scalable Lentiviral Vector Manufacturing for Gene Therapy
- Daily newsCDMO Daily News — October 2, 2026
- Biomay and Synthego Partner on Integrated cGMP CRISPR Manufacturing
- Daily newsCDMO Daily News — October 1, 2026
- SK pharmteco Commits $200M+ to Expand U.S. Small-Molecule and Peptide Manufacturing
- Piramal Pharma Solutions Secures $1.75M Ontario Grant for Aurora API Site Expansion
- Axplora Advances Exatecan GMP Supply Route for ADC Developers
- Genezen to Manufacture AAV9 Gene Therapy for N-of-1 ARCA2 Trial
- Daily newsCDMO Daily News — September 30, 2026
- Quotient Sciences Deploys AI Formulation Platform for Acesion Pharma Atrial Fibrillation Pipeline
- Daily newsCDMO Daily News — September 29, 2026
- Vetter Adds Ten Commercial Fill-Finish Lines Across Global Network Through 2031
- Daily newsCDMO Daily News — September 27, 2026
- Bramble Bio Signs 18-Month Manufacturing Agreement With VERIGRAFT for P-TEV Clinical Trial
- Daily newsCDMO Daily News — September 26, 2026
- Altruist Biologics Suzhou Facility Achieves First EMA GMP Certification
- SK pharmteco Launches Catalyst Kit for Continuous API Manufacturing
- Deep diveAPI and small-molecule CDMO outsourcing
Small-molecule API CDMOs face mounting pressure to evolve beyond manufacturing into regulatory strategy and supply-chain governance, while tier-one vendors consolidate to offer integrated end-to-end services—a shift driven by stricter data-integrity rules, surging demand for high-potency and conjugate chemistries, and pharma buyers' need
- Daily newsCDMO Daily News — September 24, 2026
- Sanner Completes Gilero Rebranding, Expands Chicago Innovation Facility
- Cellares Partners with Seoul National University Hospital on Automated Cell Therapy Manufacturing
- Daily newsCDMO Daily News — September 23, 2026
- Made Scientific Acquires Operational 85,000-Sq.-Ft. Cell Therapy GMP Facility in Pennsylvania
- Sanner Rebrands Gilero, Expands Chicago Innovation Facility
- Daily newsCDMO Daily News — September 22, 2026
- Made Scientific Acquires 85,000 sq. ft. Cell Therapy GMP Facility in Pennsylvania
- Andelyn Biosciences Launches Commercial Manufacturing of FDA-Approved Gene Therapy Fayuvi
- Daily newsCDMO Daily News — September 19, 2026
- Kincell Bio and Cellipont Merge to Form Kincellis Advanced Therapies
- Quotient Sciences' AI Algorithm Achieves Pharmacokinetic Target in Modified-Release Formulation Study
- Daily newsCDMO Daily News — September 18, 2026
- Piramal Pharma Solutions Deploys 4.3 MWp Solar Plant at UK Drug Substance/Product Facility
- ProBio and Kun Tuo (IQVIA) Launch Integrated CDMO-CRO Partnership for China Biologics Development
- Daily newsCDMO Daily News — September 16, 2026
- Argonaut Divests LSDx Unit to 1315 Capital, Reinvests in Fill-Finish Capacity
- Interlabor's Dual-Path Troubleshooting Framework Cuts Root-Cause Investigation to Days
- Daily newsCDMO Daily News — September 15, 2026
- Astellas Doubles Tralee Aseptic Capacity With Second Filling Line by 2029
- Interlabor's Dual-Path Troubleshooting Framework Cuts Root-Cause Investigation to Days
- Daily newsCDMO Daily News — September 12, 2026
- Samsung Biologics Secures $262M Long-Term Manufacturing Contract Through 2033
- Daily newsCDMO Daily News — September 11, 2026
- Cellipont and Xiogenix Validate Automated Fill-Finish for Cell Therapy Scale-Up
- CordenPharma Expands Italy Injectable Capacity to 500M Units/Year
- EpilepsyGTx Selects Viralgen for EPY201 AAV Gene Therapy Manufacturing
- Daily newsCDMO Daily News — September 6, 2026
- Northway Biotech Opens €61M Cell Therapy CDMO in Vilnius with 20 cGMP Lines
- Daily newsCDMO Daily News — September 4, 2026
- Cellipont Bioservices Advances Six Cell Therapy Programs to 2026 IND Submissions
- Northway Biotech Opens €61M Cell Therapy CDMO in Vilnius with 20 cGMP Lines
- Daily newsCDMO Daily News — September 3, 2026
- Genprex Taps Andelyn Biosciences for AAV Diabetes Gene Therapy Scale-Up
- Lifecore Biomedical Wins Commercial Injectable Transfer; Seventh Late-Stage Program in 2026
- Daily newsCDMO Daily News — September 2, 2026
- Ennolys Expands Fermentation and Bioprocessing CDMO Services
- Daily newsCDMO Daily News — September 1, 2026
- Evonik Invests $108M in Vancouver Lipid-Drug Manufacturing Facility
- Ennolys Expands CDMO Services in Fermentation, DSP, and Drying
- Daily newsCDMO Daily News — August 29, 2026
- Evonik Invests $108M in Vancouver GMP Lipid Drug-Product Facility
- Neuland, Gland Pharma Expand Sterile API Capacity via Visakhapatnam Partnership
- Daily newsCDMO Daily News — August 28, 2026
- 4basebio Expands Genezen Partnership for GMP Synthetic DNA in Viral Vector Manufacturing
- Artis BioSolutions Opens Genetic Medicines Center of Excellence in Bilbao
- Neuland, Gland Pharma Expand Sterile API Capacity via Visakhapatnam Partnership
- Daily newsCDMO Daily News — August 27, 2026
- 4basebio Expands Genezen Partnership for GMP Synthetic DNA in Viral Vector Manufacturing
- Artis BioSolutions Opens Genetic Medicines Center of Excellence in Bilbao
- Daily newsCDMO Daily News — August 26, 2026
- Cambrex High Point Site Clears FDA, PMDA, TGA Inspections for API Manufacturing
- Integrated GMP Operating Models Reshape Outsourced Manufacturing for Emerging Biopharma
- Daily newsCDMO Daily News — August 25, 2026
- Halo Pharma Nears Activation of $45M Sterile Injectable Line
- Daily newsCDMO Daily News — August 22, 2026
- Halo Pharma Activates $45M Sterile Injectable Line in New Jersey
- Daily newsCDMO Daily News — August 21, 2026
- Piramal Pharma Increases Yapan Bio Stake to 74% for $7.95M, Expands ADC Platform
- Andelyn Biosciences to Manufacture AAV9-GM2 Gene Therapy for Queen's University
- Deep diveFill finish drug product CDMO outsourcing capacity
Sterile fill-finish capacity has become the critical constraint for drug manufacturers in 2025–2026, with outsourcing hitting record levels as biologic approvals and GLP-1 demand surge faster than CDMOs can expand specialized infrastructure. Sponsors must now compete aggressively for limited slots at tier-one CDMOs while managing the risk
- Daily newsCDMO Daily News — August 20, 2026
- SK pharmteco Opens Small-Molecule and HPAPI Manufacturing Expansions in Ireland
- Cytovance Biologics Launches Standalone Analytical Services for Biologics Development
- Andelyn Biosciences to Manufacture AAV9-GM2 Gene Therapy for Queen's University
- Piramal Pharma Increases Yapan Bio Stake to 74% for $7.95M, Bolsters ADC Platform
- Genprex Partners with U.S. CDMO for AAV Diabetes Gene Therapy Scale-Up
- Daily newsCDMO Daily News — August 18, 2026
- WuXi XDC Achieves GMP Release for Singapore Bioconjugate Production Line
- Daily newsCDMO Daily News — August 15, 2026
- Cabaletta Bio Adds ElevateBio as Second CDMO Partner Alongside Lonza for Rese-cel
- NurExone Selects Made Scientific for Exclusive U.S. Exosome GMP Manufacturing
- Samsung Biologics Achieves 90-Day Dual-Site Tech Transfer for GMP Biologics Manufacturing
- Daily newsCDMO Daily News — August 12, 2026
- Cambrex Breaks Ground on $30M Milan R&D Facility; Iowa API Plant Engineering Complete
- Daily newsCDMO Daily News — August 11, 2026
- Transcenta Sells Hangzhou GMP Plant to WuXi Biologics for $26.2M
- Gland Pharma Wins $90M–$100M Sterile Injectable Manufacturing Deal
- Daily newsCDMO Daily News — August 8, 2026
- CPC Scientific Passes FDA Pre-License Inspection for Hepcludex API Manufacturing
- Altruist Biologics Completes Commercial PPQ on 20,000L Bioreactors in Hangzhou
- Gland Pharma and Neuland Laboratories Launch Sterile API CDMO Partnership in India
- Porton Advanced Gains China NMPA Class C License for Commercial CGT Manufacturing
- Deep diveMitigating FDA Drug Shortages with Contract Manufacturing
CDMOs have evolved from peripheral vendors to essential infrastructure for preventing FDA drug shortages, with sponsors now prioritizing manufacturing partner quality and tech-transfer capability over raw capacity to ensure supply resilience. This structural shift reflects lessons from COVID-19 and positions outsourcing as a decentralized
- Daily newsCDMO Daily News — August 6, 2026
- AsymBio Secures $184M to Expand Biologics Manufacturing and GMP Capacity
- CordenPharma Completes AmbioPharm Acquisition, Adds U.S. and Asia Peptide Capacity
- Altasciences Expands Harleysville R&D Lab with Integrated Formulation and Analytical Testing
- Piramal Pharma Solutions Opens Spray-Drying Suite for Peptide Formulation in India
- Taysha Secures Commercial Manufacturing with Catalent for Gene Therapy TSHA-102
- Daily newsCDMO Daily News — August 3, 2026
- CRAMSN COO: Strategic CDMO Model Requires Separate Operating Teams, Not One-Size-Fits-All Approach
- Daily newsCDMO Daily News — August 1, 2026
- AdvanCell Breaks Ground on Andover, MA Manufacturing Facility for Targeted Alpha Therapies
- Resilience and Eli Lilly Expand Ohio Manufacturing Partnership With $750M Investment
- Deep diveFill-finish outsourcing: CDMOs meet soaring demand for high-quality services
Biopharma sponsors are rapidly outsourcing fill-finish operations to specialized CDMOs as injectable therapies dominate pipelines and regulatory burdens mount, with AI-powered process control and patient-centric delivery systems becoming key competitive differentiators in a market projected to nearly double by 2034.
- Daily newsCDMO Daily News — July 30, 2026
- Cellipont Bioservices Reaches 100 GMP Batch Releases at Texas Cell Therapy Facility
- Daily newsCDMO Daily News — July 29, 2026
- AsymBio Expands Shanghai Biologics R&D with New Eight-Story Facility
- Asymchem's Jilin Carbapenem API Facility Passes First FDA Pre-Approval Inspection